## DEVELOPMENT AND ASSESSMENT OF THE IMMUNO-MODULATING ACTIVITY OF BIOTECH PRODUCTS, SMALL MOLECULES AND OTHER IMMUNO-THERAPEUTICS


Innovations and Benefits - In recent years, the open innovation model, characterized by cooperative interactions between research institutes and pharmaceutical industries, strengthened the development of innovative pharmaceuticals. The immunology area represents one of the most interesting areas for biotech companies.


ENEA has skills, knowledge and experimental models that can foster pharmaceutical companies and other stakeholders in the development of immuno-modulating drugs by using and/or developing innovative assays with procedures shifted from the basic research. ENEA also supports technology transfer to companies where, assays developed by ENEA, can be implemented to adhere to GLP and/or GMP procedures.

Uses - Pharmaceutical and biotech companies, including SME, and other stakeholders to:

- · assess the immunological effects biopharmaceuticals and small molecules;
- assess the immuno-modulating effects of natural products;
- assess therapeutic effects in experimental models for immuno-mediated diseases;
- · assessments to complement analysis required for regulatory/authorization processes;
- development of innovative assays with procedures translated from basic research.

Past and Present Activities - Collaborations with Research Toxicology Center (RTC) SpA (Menarini Group) to assess the activity of biological and biotechnology products using immunological assays and Sigma-Tau Industrie Farmaceutiche Riunite S.p.A to assess the pharmacological activity of small molecules in graft vs. host disease models.





RESEARCH TO PROVE TECHNOLOGY DEMONSTRATION SYSTEM TEST, LAUNCH & OPERATIONS

BASIC TECHNOLOGY RESEARCH TECHNOLOGY DEVELOPMENT SYSTEM/SUBSYSTEM DEVELOPMENT

TRL 1 TRL 2 TRL 3 TRL 4 TRL 5 TRL 6 TRL 7 TRL 8 TRL 9

TECHNOLOGY READINESS LEVEL

